118 related articles for article (PubMed ID: 38593868)
1. Humoral and cellular response of two different vaccines against SARS-CoV-2 in a group of healthcare workers: Comment.
Daungsupawong H; Wiwanitkit V
J Immunol Methods; 2024 Jun; 529():113671. PubMed ID: 38593868
[No Abstract] [Full Text] [Related]
2. Cellular and Humoral Immune Responses After 3 Doses of BNT162b2 mRNA SARS-CoV-2 Vaccine in Kidney Transplant.
Stumpf J; Tonnus W; Paliege A; Rettig R; Steglich A; Gembardt F; Kessel F; Kröger H; Arndt P; Sradnick J; Frank K; Tonn T; Hugo C
Transplantation; 2021 Nov; 105(11):e267-e269. PubMed ID: 34342963
[TBL] [Abstract][Full Text] [Related]
3. Humoral and T-cell immune response following three doses of SARS-CoV-2 mRNA vaccine in giant cell arteritis: analysis of a prospective cohort.
Bartoletti A; Fornara C; Delvino P; Franchi G; Ferrari A; Baldanti F; Montecucco C; Monti S
Clin Exp Rheumatol; 2024 Apr; 42(4):942. PubMed ID: 37812496
[No Abstract] [Full Text] [Related]
4. Spike Antibody Titers Evaluation after a 2-Dose Regimen of BNT162b2 Vaccination in Healthcare Workers Previously Infected with SARS-CoV-2.
Kayukawa S; Nanya K; Morita M; Ina K; Ota Y; Hasegawa S
Microbiol Spectr; 2021 Dec; 9(3):e0103621. PubMed ID: 34756062
[No Abstract] [Full Text] [Related]
5. SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response.
Mileto D; Fenizia C; Cutrera M; Gagliardi G; Gigantiello A; De Silvestri A; Rizzo A; Mancon A; Bianchi M; De Poli F; Cuomo M; Burgo I; Longo M; Rimoldi SG; Pagani C; Grosso S; Micheli V; Rizzardini G; Grande R; Biasin M; Gismondo MR; Lombardi A
Emerg Microbes Infect; 2021 Dec; 10(1):2235-2243. PubMed ID: 34749573
[TBL] [Abstract][Full Text] [Related]
6. Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer.
McKenzie DR; Muñoz-Ruiz M; Monin L; Alaguthurai T; Lechmere T; Abdul-Jawad S; Graham C; Pollock E; Graham R; Sychowska K; Seow J; Tremain C; Gousis C; Domingo-Vila C; Cooper J; Vidler J; Owczarczyk K; Swampillai A; Kristeleit H; Malim MH; Fields P; Patten PEM; Papa S; North BV; Tree T; Doores KJ; Hayday AC; Irshad S
Cancer Cell; 2021 Nov; 39(11):1445-1447. PubMed ID: 34678151
[No Abstract] [Full Text] [Related]
7. Impact of Kidney Transplantation on Humoral Immunity Against SARS-CoV-2: A Case Series From Belgium.
Fernandes G; Devresse A; Scohy A; Yombi JC; Belkhir L; De Greef J; De Meyer M; Mourad M; Darius T; Buemi A; Kabamba B; Goffin E; Kanaan N
Transplantation; 2021 Nov; 105(11):e257-e258. PubMed ID: 34347716
[No Abstract] [Full Text] [Related]
8. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
[TBL] [Abstract][Full Text] [Related]
9. Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.
Lozano-Rodríguez R; Valentín-Quiroga J; Avendaño-Ortiz J; Martín-Quirós A; Pascual-Iglesias A; Terrón-Arcos V; Montalbán-Hernández K; Casalvilla-Dueñas JC; Bergón-Gutiérrez M; Alcamí J; García-Pérez J; Cascajero A; García-Garrido MÁ; Balzo-Castillo ÁD; Peinado M; Gómez L; Llorente-Fernández I; Martín-Miguel G; Herrero-Benito C; Benito JM; Rallón N; Vela-Olmo C; López-Morejón L; Cubillos-Zapata C; Aguirre LA; Fresno CD; López-Collazo E
Cell Rep; 2022 Jan; 38(2):110235. PubMed ID: 34986327
[TBL] [Abstract][Full Text] [Related]
10. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
[No Abstract] [Full Text] [Related]
11. Humoral Response to mRNA versus an Adenovirus Vector-Based SARS-CoV-2 Vaccine in Dialysis Patients.
Mulhern JG; Fadia A; Patel R; Ficociello LH; Willetts J; Dahne-Steuber IA; Pollan MC; Mullon C; DeLisi J; Johnson C; Mysayphonh C; Kossmann RJ; Anger MS; Hymes JL
Clin J Am Soc Nephrol; 2021 Nov; 16(11):1720-1722. PubMed ID: 34312162
[No Abstract] [Full Text] [Related]
12. Influence of past infection with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers: Kinetics and durability of the humoral immune response.
Ontañón J; Blas J; de Cabo C; Santos C; Ruiz-Escribano E; García A; Marín L; Sáez L; Beato JL; Rada R; Navarro L; Sainz de Baranda C; Solera J
EBioMedicine; 2021 Nov; 73():103656. PubMed ID: 34740112
[TBL] [Abstract][Full Text] [Related]
13. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
Manisty C; Otter AD; Treibel TA; McKnight Á; Altmann DM; Brooks T; Noursadeghi M; Boyton RJ; Semper A; Moon JC
Lancet; 2021 Mar; 397(10279):1057-1058. PubMed ID: 33640038
[No Abstract] [Full Text] [Related]
14. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.
Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M
Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593
[TBL] [Abstract][Full Text] [Related]
15. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
16. Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers.
Ramos A; Martins S; Marinho AS; Norton P; Cardoso MJ; Guimarães JT
PLoS One; 2024; 19(5):e0303244. PubMed ID: 38728294
[TBL] [Abstract][Full Text] [Related]
17. Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses.
Tauzin A; Gong SY; Beaudoin-Bussières G; Vézina D; Gasser R; Nault L; Marchitto L; Benlarbi M; Chatterjee D; Nayrac M; Laumaea A; Prévost J; Boutin M; Sannier G; Nicolas A; Bourassa C; Gendron-Lepage G; Medjahed H; Goyette G; Bo Y; Perreault J; Gokool L; Morrisseau C; Arlotto P; Bazin R; Dubé M; De Serres G; Brousseau N; Richard J; Rovito R; Côté M; Tremblay C; Marchetti GC; Duerr R; Martel-Laferrière V; Kaufmann DE; Finzi A
Cell Host Microbe; 2022 Jan; 30(1):97-109.e5. PubMed ID: 34953513
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
19. Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis.
Strengert M; Becker M; Ramos GM; Dulovic A; Gruber J; Juengling J; Lürken K; Beigel A; Wrenger E; Lonnemann G; Cossmann A; Stankov MV; Dopfer-Jablonka A; Kaiser PD; Traenkle B; Rothbauer U; Krause G; Schneiderhan-Marra N; Behrens GMN
EBioMedicine; 2021 Aug; 70():103524. PubMed ID: 34391096
[TBL] [Abstract][Full Text] [Related]
20. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
Front Immunol; 2021; 12():727850. PubMed ID: 34671350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
